此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Sutent + Taxol for Advanced Esophageal Cancer

2017年1月26日 更新者:Nasser Hanna, M.D.、Hoosier Cancer Research Network

A Phase II Study of Sunitinib Malate (Sutent®) With Paclitaxel (Taxol®) in Patients With Advanced Esophageal Cancer

Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens. Sunitinib malate is an anti-angiogenic drug with the potential to improve responses when combined with chemotherapy, as demonstrated with other regimens in similar settings. We believe that the combination of paclitaxel and sunitinib malate offer great promise in the treatment of advanced esophageal cancer.

研究概览

地位

完全的

条件

详细说明

OUTLINE: This is a multi-center study.

Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle.

  • Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
  • Sunitinib malate 37.5 mg orally, daily.

After 4 cycles, paclitaxel will be discontinued and patients will continue on sunitinib malate until disease progression, unacceptable toxicity, or physician discretion.

Performance Status: ECOG (Eastern Cooperative Oncology Group) performance status 0 to 2

Life expectancy: Not specified

Hematopoietic:

  • International Normalized Ratio (INR) < 1.2
  • Partial Thromboplastin Time (PTT) < 1.5 x Upper Limit of Normal (ULN)
  • Platelets > 100 K/mm3
  • Hemoglobin > 8 g/dL
  • Absolute Neutrophil Count (ANC) > 1.0 K/mm3

Hepatic:

  • Aspartate transaminase (AST) ≤ 2.5 x ULN, or ≤ 5.0 x ULN if the transaminase elevation is due to known liver metastases.
  • Alanine transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5.0 x ULN if the transaminase elevation is due to known liver metastases.
  • Total bilirubin < 2.0 x ULN

Renal:

  • Serum creatinine ≤ 2 x ULN or a calculated creatinine clearance (using Cockcroft-Gault formula) > 50 cc/min

Cardiovascular:

  • No history of unstable angina, myocardial infarction, coronary artery bypass grafting surgery within 12 months prior to registration for protocol therapy. Patients may be on anti-anginal medications, but must be stable on those medications for at least 6 months.
  • No history of New York Heart Association class II or greater congestive heart failure.

Pulmonary:

  • Not specified

研究类型

介入性

注册 (实际的)

28

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Illinois
      • Chicago、Illinois、美国、60611
        • Northwestern University Feinberg School of Medicine
      • Chicago、Illinois、美国、60612
        • Rush-Presbyterian St. Luke's Medical Center
      • Galesburg、Illinois、美国、61401
        • Medical & Surgical Specialists, LLC
    • Indiana
      • Bloomington、Indiana、美国、47403
        • Cancer Care Center of Southern Indiana
      • Evansville、Indiana、美国、47714
        • Oncology Hematology Associates of SW Indiana
      • Fort Wayne、Indiana、美国、46815
        • Fort Wayne Oncology & Hematology, Inc
      • Indianapolis、Indiana、美国、46202
        • Indiana University Simon Cancer Center
      • Indianapolis、Indiana、美国、46202
        • IN Onc/Hem Associates
      • Lafayette、Indiana、美国、47905
        • Horizon Oncology Center
      • Lafayette、Indiana、美国、47904
        • Arnett Cancer Care
      • Muncie、Indiana、美国、47303
        • Medical Consultants, P.C.
      • Munster、Indiana、美国、46321
        • Monroe Medical Associates
      • South Bend、Indiana、美国、46601
        • Northern Indiana Cancer Research Consortium
      • Terre Haute、Indiana、美国、47802
        • Providence Medical Group
    • Ohio
      • Cleveland、Ohio、美国、44106
        • Ireland Cancer Center - University Hospitals of Cleveland

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologically confirmed recurrent or metastatic esophageal or gastro-esophageal junction squamous cell or adenocarcinoma
  • Measurable or evaluable disease per RECIST within 28 days prior to being registered on protocol therapy.
  • No more than one prior chemotherapy regimen for locally advanced or metastatic disease is allowed.
  • Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  • Age > 18 years.
  • Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) while on treatment and for 3 month period thereafter.
  • Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy. Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
  • Females must not be breastfeeding.
  • Must be willing to comply with study and follow up procedures.

Exclusion Criteria:

  • No history of inadequately controlled hypertension (Systolic Blood Pressure > 150 or Diastolic Blood Pressure > 100) on a standard regimen of antihypertensive therapy.
  • No prior treatment with vascular endothelial growth factor (VEGF) inhibitor, epidermal growth factor receptor (EGFR) inhibitor, or other anti-angiogenic agent.

No serious, non-healing wound, ulcer, or bone fracture.

  • No history of or current hemoptysis.
  • No history of transient ischemic attack (TIA) or stroke within 12 months prior to registration for protocol therapy.
  • No evidence of bleeding diathesis, coagulopathy, prolonged INR or PTT.
  • No chronic anti-coagulation treatment.
  • No history of central nervous system or brain metastases.
  • No history of any major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration for protocol therapy, or anticipation of need for major surgical procedure during the course of protocol therapy.
  • No history of any minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to registration for protocol therapy.
  • No history of clinically significant peripheral neuropathy, i.e., Grade > 3 neuromotor or neurosensory toxicity as defined by NCI CTCAE v 3.0.
  • No known history of adrenal insufficiency documented by adrenocorticotropic hormone (ACTH) stimulation testing.
  • No prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (> 450 msec), obtained within 28 days prior to being registered for protocol therapy.
  • No other active cancers
  • No clinically significant infections as judged by the treating investigator.
  • No history of a seizure disorder.
  • No known history of hypersensitivity to paclitaxel.
  • No CYP3A4 inducers and inhibitors allowed within 14 days prior to registration on protocol therapy and while receiving the protocol therapy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:1

Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle.

  • Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
  • Sunitinib malate 37.5 mg orally, daily. After 4 cycles, paclitaxel will be discontinued and patients will continue on sunitinib malate until disease progression, unacceptable toxicity, or physician discretion.
Sunitinib malate 37.5 mg orally, daily
Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression Free Survival Rate at 24 Weeks
大体时间:24 weeks
To determine the rate of non-progressive disease at 24 weeks from the first dose of the combination of sunitinib malate and paclitaxel in advanced esophageal carcinoma, where progression is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions
24 weeks

次要结果测量

结果测量
措施说明
大体时间
Response Rate
大体时间:6 months
To determine the response rate for the combination of sunitinib malate and paclitaxel in advanced esophageal carcinoma per RECIST criteria.
6 months
Overall Survival
大体时间:12 months
To determine the one year overall survival rate for the combination of sunitinib malate and paclitaxel in advanced esophageal carcinoma
12 months
Progression-Free Survival
大体时间:12 months
To determine the time to progression for the combination of sunitinib malate and paclitaxel in advanced esophageal carcinoma per RECIST criteria.
12 months
Toxicity Profile
大体时间:16 months
Determine the most frequent toxicities associated with the treatment regimen, per the CTCAE version 3 (Common Toxicity Criteria for Adverse Events) criteria.
16 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2008年8月1日

初级完成 (实际的)

2010年3月1日

研究完成 (实际的)

2010年3月1日

研究注册日期

首次提交

2008年8月4日

首先提交符合 QC 标准的

2008年8月6日

首次发布 (估计)

2008年8月8日

研究记录更新

最后更新发布 (实际的)

2017年3月16日

上次提交的符合 QC 标准的更新

2017年1月26日

最后验证

2017年1月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅